Total (n=1445) | |
n (%) | |
Age (years), median (range) | 45 (18–90) |
Male | 1306 (90.4) |
AIDS-defining conditions* | 915 (63.3) |
Hospital admission† | |
No | 1121 (77.6) |
Yes | 324 (22.4) |
For an AIDS-defining condition‡ | 120 (8.3) |
For non-AIDS-defining conditions only§ | 196 (13.6) |
For unknown reason¶ | 8 (0.6) |
Chronic comorbidity | |
Diabetes | 387 (26.8) |
Hypertension | 263 (18.2) |
Lipid disorders | 456 (31.6) |
Vascular diseases | 55 (3.8) |
Kidney failure | 78 (5.4) |
Malignancies | 117 (8.1) |
Psychiatric disorders | 219 (15.2) |
Osteoporosis | 85 (5.9) |
Hepatitis B/C coinfection | 263 (18.2) |
Use of a non-antiretroviral medication** | 1086 (75.2) |
Type of key drug among antiretrovirals | |
INSTI | 789 (54.8) |
NNRTI | 359 (24.9) |
PI | 617 (42.8) |
*Patients were considered to have an AIDS-defining condition if they had at least one disease record of AIDS-defining conditions during the study period. The only exception is for recurrent pneumonia; patients were considered to have recurrent pneumonia only when they had two or more codes of pneumonia (J12‒18/B01.2) recorded within 18 months.
†Hospital admissions for any cause during the study period.
‡Patients with at least one record of hospital admission and whose reason for admission included an AIDS-defining condition.
§Patients with at least one record of hospital admission and whose reason for admission was only non-AIDS-defining conditions.
¶Patients with at least one record of hospital admission and whose reason for admission was unknown (ie, no data available).
**Non-antiretroviral medication prescribed for use for ≥30 days total during the study period was taken into consideration.
INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.